In a recently published long‐term follow up of SOFT and TEXT, cancer outcomes were numerically in favor of tamoxifen over an AI as the oral ET partner in combination with OS in HER2+ disease (13 year DRFI 87.9% tamoxifen + OS vs. 80.4% AI + OS; absolute difference−7.5 (95% CI‐13.8‐1.2)).7 This evidence concerns the gene ERBB2 and cancer.